Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anaptysbio (ANAB) EBITDA Margin (2016 - 2025)

Anaptysbio's EBITDA Margin history spans 10 years, with the latest figure at 66.06% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 15501.0% year-over-year to 66.06%; the TTM value through Dec 2025 reached 7.75%, up 24011.0%, while the annual FY2025 figure was 5.78%, 15212.0% up from the prior year.
  • EBITDA Margin reached 66.06% in Q4 2025 per ANAB's latest filing, up from 30.33% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 66.06% in Q4 2025 to a low of 3945.05% in Q1 2022.
  • Average EBITDA Margin over 5 years is 1039.9%, with a median of 437.45% recorded in 2024.
  • The largest YoY upside for EBITDA Margin was 272732bps in 2022 against a maximum downside of -376235bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 3240.36% in 2021, then skyrocketed by 84bps to 513.04% in 2022, then increased by 12bps to 451.5% in 2023, then soared by 80bps to 88.95% in 2024, then surged by 174bps to 66.06% in 2025.
  • Per Business Quant, the three most recent readings for ANAB's EBITDA Margin are 66.06% (Q4 2025), 30.33% (Q3 2025), and 174.27% (Q2 2025).